Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Heron Therapeutics (HRTX) over the last 10 years, with Q3 2025 value amounting to -$11.3 million.

  • Heron Therapeutics' Other Non Operating Income fell 280743.59% to -$11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.6 million, marking a year-over-year decrease of 58936.45%. This contributed to the annual value of $430000.0 for FY2024, which is 2321.43% down from last year.
  • Latest data reveals that Heron Therapeutics reported Other Non Operating Income of -$11.3 million as of Q3 2025, which was down 280743.59% from -$744000.0 recorded in Q2 2025.
  • Heron Therapeutics' 5-year Other Non Operating Income high stood at $2.0 million for Q4 2024, and its period low was -$11.3 million during Q3 2025.
  • Over the past 5 years, Heron Therapeutics' median Other Non Operating Income value was -$445000.0 (recorded in 2021), while the average stood at -$1.1 million.
  • As far as peak fluctuations go, Heron Therapeutics' Other Non Operating Income skyrocketed by 45525.42% in 2024, and later tumbled by 280743.59% in 2025.
  • Over the past 5 years, Heron Therapeutics' Other Non Operating Income (Quarter) stood at $868000.0 in 2021, then skyrocketed by 52.3% to $1.3 million in 2022, then crashed by 105.98% to -$79000.0 in 2023, then surged by 2596.2% to $2.0 million in 2024, then crashed by 675.0% to -$11.3 million in 2025.
  • Its last three reported values are -$11.3 million in Q3 2025, -$744000.0 for Q2 2025, and -$519000.0 during Q1 2025.